METHOD FOR BINDING ACTIVE AGENTS TO ACTIVATED AUTOLOGOUS BLOOD NOSODES AND DEVICE FOR CARRYING OUT THE METHOD

Description

Field of invention

[0001] The invention relates to a method for binding active agents to activated autologous blood nosodes and to a device for carrying out the method. Background of the invention

[0002] Autologous blood therapy has become widely known, not least because it is on the list of prohibited doping substances. In this procedure, blood is drawn from the patient and then reinjected into the patient at a different location on the body. Variations exist, such as irradiating the blood with UV-C light, enriching it with an ozone-oxygen mixture, or adding nosodes, other homeopathic preparations, or immunostimulants like echinacea before reinjecting the blood into the patient.

[0003] Less well-known are the so-called autologous blood nosodes (also known as autologous blood therapy according to Imhäuser). To prepare them, a drop of blood from the fingertip or earlobe is usually diluted with aqueous ethanol (e.g., 10 or 20 ml) or triturated with, for example, sucrose or xylitol and processed into globules. The resulting dispersion or the globules are then administered orally to the patient in doses of several drops per day. This initial dilution can be further diluted according to the principles of homeopathy, either in the form of a solution or in the form of globules. Autologous blood nosodes are primarily used, for example, for allergic and skin diseases as well as for recurrent infectious diseases. A non-specific regulatory reaction is suspected as the mechanism of action.

[0004] Blood is known to consist of erythrocytes, leukocytes, thrombocytes and blood plasma, the latter of which consists of approximately 90% water and approximately 10% dissolved substances, mainly salts and buffers (acids / bases) as well as proteins (e.g. albumin and coagulation factors).

[0005] The important protein albumin (or human serum albumin (HSA)) primarily serves to maintain the osmotic pressure of the blood and to transport water-insoluble substances in the blood. It also acts as a disaggregator for erythrocytes and platelets. HSA is an amphoteric protein with a molecular mass of approximately 66,470 Da. It is elliptical in shape with a relatively hard core and a flexible surface structure (Münnemann, Kerstin; Hinderberger, Dariush; Research Report from Webservice 2011 - Max Planck Institute for Polymer Research (http: / / www.mpip-Mainz.mpg.de / 20689 / research_report_1179941?c=22413)).

[0006] In medicine, it has been known for some time that binding drugs to HSA can offer significant advantages, such as a reduction in the required drug dosage, fewer side effects, and more targeted delivery of the drug to the site of disease. The binding of the drug to the HSA was achieved either through covalent bonding (e.g., methotrexate-HSA or aminopterin-HSA) or, in the case of nab (nanoparticle albumin-bound)-paclitaxel, through high-pressure homogenization of amorphous paclitaxel in the presence of HSA to form a colloidal nanoparticle suspension.

[0007] Ordinary nosodes (i.e., not autologous blood nosodes), the name derived from the Greek word "nosos" ("disease"), are produced according to the regulations of the HAB (German Homeopathic Pharmacopoeia) from (highly weakened or killed) pathogens, pathological material such as the blood of a patient, pus, or cells from organs, e.g., cancer cells, or bodily secretions / excretions, including, for example, hormones (more than 2,000 nosodes are currently commercially available). In the nosode, the principle of vaccination (stimulating the body's self-healing powers by exposing it to a weakened disease stimulus) is combined with the principle of homeopathy. The term "nosode" was coined around 1830 by the American physician Constantin Hering. However, the principle itself has been known since antiquity. As early as 800 BC, the Chinese used diluted smallpox secretions, which were scratched under the skin to prevent the disease.Hippocrates also taught "to cure evil with evil," and the British philosopher and physician Robert Fludd described the treatment of consumptives with dilutions of their sputum.

[0008] The preparation of autologous blood nosodes, in accordance with the regulations of the German Homeopathic Pharmacopoeia (HAB 2016), is disclosed, for example, by Hirth et al. (Hirt HD., Kunkel M., Schmidt M.: "Preparation of Autologous Blood Nosodes in the Pharmacy" (2007) DEUTSCHE APOTHEKER ZEITUNG, 147(19): pp. 62-65). In particular, the collection of capillary blood, the preparation of a C1 alcohol-blood mixture, and further potentization up to C5 are disclosed. Treatment of the nosodes beyond potentization is not described.

[0009] Hug et al. (Hug K, Röösli M. "Therapeutic effects of whole-body devices applying pulsed electromagnetic fields (PEMF): a systematic literature review." (2016) Bioelectromagnetics, 33(2):pp. 95-105) disclose whole-body therapies using pulsed electromagnetic fields with a magnetic flux density in the range of 3.4 to 200 µT. In the disclosed therapies, the patient's entire body is exposed to pulsed electromagnetic fields for therapeutic purposes.

[0010] RU 2305414 C2 discloses a device for producing biologically active substances in which the substances are exposed to an electromagnetic field with a frequency of 0 to 10 Hz and an undisclosed field strength. The substances may be nosodes. Mixtures of autologous blood nosodes and another active substance are not disclosed.

[0011] The aim of the invention was to combine the advantages of an autologous blood nosode with the advantages of binding an active substance or agent to HSA, i.e. to load the HSA present in the autologous blood nosode with an active substance or agent in an effective but as gentle a manner as possible. Summary of the invention

[0012] The invention relates to a method for binding an active substance or an active agent to an activated autologous blood nosode, comprising: a) Dissolving a patient's blood in an aqueous or aqueous / ethanolic medium or triturating a patient's blood with a carrier substance approved for globules according to the German Homeopathic Pharmacopoeia (HAB) to obtain an initial mixture; b) Activating the initial mixture by applying magnetic pulses with magnetic field period frequencies within a range of approximately 0.01 to approximately 20,000 Hz and field strengths of a maximum of 50 µT to the initial mixture to obtain an activated initial mixture; c) Adding a orone or more active substances and / or active agents to the activated first mixture to obtain a second mixture; d) shaking the second mixture by mechanical action, wherein steps c) and d) are carried out and the magnetic pulses are continuously applied, and wherein steps c) and d) can be repeated once or several times, resulting in a shaken second mixture; and e) activating the shaken second mixture by further continuous application of the magnetic pulses and irradiation of visible, LED-generated light of changing color into the shaken second mixture, thereby increasing the binding capacity of human serum albumin (HSA) in the blood to the active substance(s) and / or to at least parts of the active agent or active agents, and resulting in a modified autologous blood nosode.

[0013] Furthermore, the invention relates to a device for carrying out the method according to the invention, comprising: 1) a lockable housing, 2) a sample holder arranged in the housing which can hold a transparent vessel in which the first mixture of step a) or b) is prepared or contained, 3) a device which can repeatedly cause mechanical vibration and / or translational movement of the vessel, 4) a magnetic coil which can generate magnetic pulses directed at the vessel with magnetic field period frequencies in the range of about 0.01 to about 20,000 Hz and field strengths of up to 50 µT; and 5) a device which includes LEDs which can generate visible light with at least two colors and shine the generated light into the vessel. Brief description of the drawing

[0014] Fig. 1 shows a schematic sectional view along line aa of Fig. 2an embodiment of a device according to the invention. Fig. 2 shows a schematic top view of the device of Fig. 1 Fig. 3 shows a front top view of the device. Fig. 1 . Detailed description

[0015] The autologous blood nosode used in the invention is preferably a suspension of one drop to 3 ml, preferably 2 ml of blood in 0.5 ml to 20 ml, preferably 1 ml to 10 ml of 40 to 85% by volume ethanol, e.g., 0.5 ml of blood in 2 ml of 70% ethanol or 2 ml of blood in 5 ml of 70% ethanol. However, in cases of alcohol intolerance in the patient and in children, physiological saline solution (0.9% NaCl solution) or conventional solid globule carrier substances, such as sucrose or xylitol, can also be used for dilution.

[0016] This autologous blood nosode is activated by magnetic pulses within a frequency range of 0.01 to 20,000 Hz and a magnetic field strength of up to 50 µT. The pulses are preferably so-called needle pulses and exhibit, for example, a sawtooth shape. Frequently, packets of needle pulses of similar shape but with varying field strength are used; for example, several consecutive pulse packets of similar shape but with varying field strength can be used over a period of, for example, approximately 10 to 20 µs with a pause of approximately 55 to 75 µs between the pulse packets. Suitable magnetic pulses are supplied, for example, by a vita-life® magnetic rod (available from VITA LIFE HandelsgmbH, Gewerbepark 1, 9220 Velden-Lind, Austria). The initial activation preferably takes place over a period of approximately 0.5 to 10 minutes, for example, over approximately 1 or 2 to 5 minutes.

[0017] It is known that pulsed magnetic fields of a suitable frequency have an effect on blood. This is well documented for iron-containing erythrocytes, but other charged or polarizable blood components are also affected by magnetic fields. It is assumed that in the case of HSA, with its many positively and negatively charged molecular fragments, the conformation of the molecule is influenced by the magnetic pulses.

[0018] The active substances and agents added to the activated autologous blood nosode can be selected from ordinary nosodes, ordinary homeopathic remedies (both referred to herein as "agents"), and allopathic active substances (both naturally occurring and synthetic). The selection depends on the patient's clinical picture and is determined by the treating therapist. Allopathic active substances are added only in very small quantities, so that the transport capacity of the HSA in the autologous blood nosode is not exceeded.

[0019] To name just a few examples, homeopathic active ingredients can include... Hepar Comp (Heel), Hypophysis / Stannum (Wala) and Cuorum Injectopas (Pascoe); as nosodes FSME C30, Herpes Zoster Injeel (Heel), Herpes vulgaris Injeel (Heel), Sanukehl® Staph D5 / Staphyllococcus aureus D5 ampoules and EBV C30 and as allopathic active substances alpha-lipoic acid, 600 mg folic acid Forte Hevert; in a quantity of 20 mg pyrdoxine hydrochloride (vitamin B6); in a quantity of 25 mg and Regeneresen (RNA fresh cells; Dyckerhoff Pharma) are added to the autologous blood nosode.

[0020] Usually, up to four active agents or substances are added to the autologous blood nosode before the mechanical action is performed. In special cases, however, mechanical action may also take place after each addition before the further activation step with light is carried out.

[0021] The activated autologous blood nosode is mixed with the active substances / agents by brief mechanical action, e.g., percussion of the vessel ("tapping") or, as in the case of fresh cells, repeated rapid translational movements of the vessel ("shaking"). The brief mechanical percussion or the brief translational movement of the vessel are preferably performed approximately 20 to 150 times (depending on the active substance / agent being added).

[0022] The mixture or modified autologous blood nosode thus obtained is further activated by magnetic pulses in the same manner as described above for the initial autologous blood nosode, and additionally irradiated with visible light of changing colors generated by LEDs, e.g., with two or more, preferably three or four or more, more preferably five or six or even more colors, generally for about 0.5 to about 10 minutes, e.g., for about 1 to about 5 minutes, and further preferably with a luminance in the range of 3000 to 5000 mcd, for example, 4000 mcd. It is known from complementary medicine that monochromatic light in the visible range has diverse effects on blood, one of which is the increase in the binding capacity of HSA.In addition to the magnetic pulses described above, which are also applied during light illumination, the light can be guided through a magnetic field with a field strength of approximately 50 µT downstream of the LEDs. This magnetic field can be further modulated by additional magnetic pulses, e.g., with a field strength of 20 µT and frequencies in the range of 120–140 Hz and approximately 90 kHz. A device with suitable LEDs, which also includes a permanent magnet and a magnetic coil for generating suitable permanent and pulsating magnetic fields, is available under the trade name FW-Pen from Prof. Schaack, CE, Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen, Germany.

[0023] The steps described above for adding one or more active agents / substances can be repeated up to six or seven times, preferably up to four times, with the initially prepared autologous blood nosode.

[0024] In the autologous blood nosode, modified with one or more active substances / agents as described above and activated with magnetic pulses and light, the active substances / agents (or at least some of the agents) are present in close association with HSA. This ensures their efficient transport to the site where their effect is desired.

[0025] A device for carrying out the above-described method according to the invention comprises: a) a lockable housing, b) a sample holder arranged in the housing which can hold a transparent vessel in which the first mixture of step a) or b) is prepared or contained, c) a device which can repeatedly cause mechanical vibration and / or translational movement of the vessel, d) a magnetic coil which can generate magnetic pulses directed at the vessel with magnetic field period frequencies in the range of about 0.01 to about 20,000 Hz and field strengths of up to 50 µT; and e) a device which includes LEDs which can generate visible light of different colors and shine the generated light into the vessel.

[0026] The housing can be any lockable metal or plastic housing.

[0027] The transparent vessel may have a removable septum through which the necessary liquids for preparing the nosode are injected. Solids can be introduced after removing the septum.

[0028] The sample holder b) is generally a clamp-like device into which the vessel is clamped. It may be designed to be movable, allowing for a swiveling or shaking motion (an alternative to the device c)).

[0029] Generally, mechanical vibration of the vessel is also required. This can be achieved, for example, by a hammer-like tapping device (another alternative of the device c)).

[0030] In another embodiment, the sample holder and a device capable of both mechanically vibrating the vessel and performing a translational movement are formed as a single unit. This could, for example, be a sample holder connected to a lifting device that can be moved up and down a rod-shaped support, for instance, by means of an electric motor. The downward movement can be combined with an impact against a surface, thereby mechanically vibrating the vessel and its contents.

[0031] Furthermore, the vessel contains a metal, preferably copper, magnetic coil which, when suitable electric currents are passed through it, can generate magnetic pulses with magnetic field period frequencies in the range of approximately 0.01 to approximately 20,000 Hz and field strengths of up to 50 µT. In a preferred embodiment, the coil is arranged cylindrically around the vessel and is provided with a magnetically permeable covering.

[0032] Furthermore, the vessel contains LEDs that generate visible light with at least two, preferably at least three or four, more preferably five colors or even more, as well as their mixed colors, and that can shine into the transparent vessel. For example, strips comprising such LEDs are commercially available.

[0033] The container also contains the power supply required for the aforementioned equipment, as well as equipment for controlling this equipment, possibly by means of an electronic control system using a programmed or programmable chip.

[0034] On the outside, the vessel may, for example, have an on / off switch, a display device, a counter for counting the procedures performed, a device for setting the number of mechanical earth vibrations or translational movements, and a USB port or other device for reading data. The operating control for these devices is also contained within the housing.

[0035] The container may also contain a permanent magnet with a permanent magnetic field of 50 µT or less.

[0036] Figure 1 shows a sectional view along line aa of Fig. 2In an embodiment of the device according to the invention 1. A transparent container (e.g., a specimen vial) 5, which is provided with a septum 6, is located in a holder 18 in a vessel 2, which can be closed with a lid 3. The holder 18 is connected via an arm 17 to a lifting device 16. The lifting device 16 can be moved up and down on the holder 15 by means of an electric motor (not shown), and can be moved downwards to such an extent that it can cause the vessel to strike an intermediate base plate 25.

[0037] The transparent vessel is cylindrically surrounded by a copper coil 10 covered with plastic, which extends from the intermediate base plate 25 to a height slightly below the support 18, if this is at the lowest point, at or below which is the surface of an autologous blood nosode 7 located in the vessel.

[0038] On the side of the enclosed coil facing the vessel, an LED strip 11 with LEDs 12 is arranged in a helical pattern, which can generate light with five different wavelength ranges in the visible range of the electromagnetic spectrum as well as mixed colors from them,

[0039] Below the intermediate floor plate 25, within a control and supply unit 20, there is a mains-connectable power supply 24, which supplies power via cable 21 to the coil 10, the LEDs 12 and the electric motor for the lifting device 16, an electronic control unit 23 for controlling the coil 10, the LEDs 12 and the electric motor for the lifting device 16, and an operating control unit 22 for controlling the devices located on the outside of the device, namely a display device 31, a device 32 for setting the number of movements of the lifting device 16, an on / off switch 30, a counter 33 for the number of procedures carried out in the device, and a USB port 34. Examples Example 1: Patient Mr. H. from Frankfurt, born in 1936 A) Clinical picture

[0040] This patient developed a full-body eczema with severe itching shortly after receiving a TBE vaccination. Six weeks of medical treatment with various allopathic medications, including cortisone ointments, resulted in no improvement. B) Nosode production on June 9, 2014

[0041] 0.5 ml of the patient's blood was dissolved in 5 ml of 70% ethanolic solution in a preparation vial and magnetically activated for 5 minutes using a vita-life® magnetic wand (available from VITA LIFE HandelsgmbH, Gewerbepark 1, 9220 Velden-Lind, Austria). The agents described below were then added while the magnetic wand was used for further activation. 30 drops of Q80 from Calendula 0,5 ml 10 globules of FSME nosode C30 0,5ml 1 ampoule of Hypophysis / Stannum 1,0 ml

[0042] The mixture was then shaken under continuous magnetic field activation by repeatedly striking the sample glass against a base 120 times and irradiated for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0043] A second addition of medication occurred as follows: 1 ampoule of Histamine Injeel Heel 2,0ml 1 ampoule of Calcium Carbonicum Injeel Heel 2,0ml 1 ampoule of Glandula Thymi Injeel Heel 2,0ml 1 ampoule of Coenzyme Comp. 2,0ml Total volume of added drugs 10 ml

[0044] The modified end autologous blood nosode was then shaken under further continuous magnetic field activation by repeatedly striking the preparation glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen). C) Intake of the modified autologous blood nosode

[0045] The modified autologous blood nosode, prepared as described above, was administered orally to the patient, 10 drops three times daily, for a period of five days. The nosode must remain in the mouth for two minutes (to allow for salivation) without being swallowed. D) Treatment outcome according to the patient's statement

[0046] The patient experienced relief from itching within just a few hours. Significant improvement in the eczema began as early as the second day after taking the nosode. After one week, the eczema had almost completely healed. The patient is currently undergoing follow-up therapy (biological regenerative medicine according to C. Klein). Example 2: Patient Mrs. M. from Remshalden, born in 1942 A) Clinical picture

[0047] The patient had bronchial asthma and pulmonary emphysema with severe respiratory impairment due to right lung segments being removed 15 years prior. Only one-third of the right lung remains.

[0048] Her allopathic medication consisted of: Viani mite 50 / 100 Spiriva B) Nosode preparation on June 21, 2014

[0049] 0.5 ml of the patient's blood was dissolved in 5 ml of 70% ethanolic solution in a preparation vial and magnetically activated for 5 minutes using a vita-life® magnetic wand (available from VITA LIFE HandelsgmbH, Gewerbepark 1, 9220 Velden-Lind, Austria). The agents described below were then added while the magnetic wand was used for further activation. 20 drops ionized. Phosphorus D6 0,5ml 15 drops of Calendula breath extract 0,5ml 3 ampoules N. Vagus GI D6 Wala 3 x 2 ml = 6.0 ml

[0050] The mixture was then shaken under continuous magnetic field activation by repeatedly striking the sample glass against a base 150 times and irradiated for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0051] A second addition of medication occurred as follows: 2 ampoules of Injectio antiasthmatica Heel 2 x 1 ml = 2.0 ml 2 ampoules Medulla oblongata Injeel Heel 2 x 2 ml = 4.0 ml

[0052] Then, this mixture was shaken under continued magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0053] A third addition of medication occurred as follows: 2 ampoules of Bronchus suis Injeel Heel 2 x 2 ml = 4.0 ml 1 ampoule of Hypothalamus suis Injeel Heel 2,0ml

[0054] Then, this mixture was shaken under continued magnetic field activation by repeatedly striking the sample glass against a base 150 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0055] A fourth and final addition of medicines occurred as follows: 1 ampoule of Glandula Thymi suis Injeel Heel 2,0ml 1 ampoule ATP Heel 2,0ml 12 drops of joie de vivre from Calendula 0,5ml 5 drops of Colchicum Hevert 0,5ml Total volume of added drugs 24 ml

[0056] The modified end autologous blood nosode thus obtained was then shaken under further continuous magnetic field activation by impacting the preparation glass on a base 150 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen). C) Intake of the modified autologous blood nosode

[0057] The modified autologous blood nosode, prepared as described above, was administered orally to the patient, 10 drops 5 times daily, for a period of 14 days. The nosode must remain in the mouth for 2 minutes (to mix with saliva) without being swallowed.

[0058] For the nosode, 1 pump of Spenglersan Kolloid T from Meckel was administered 5 times daily into the left and right elbow crease. D) Treatment outcome according to medical observation and patient statement

[0059] A significant improvement in breathing was observed just 5 minutes after taking the nosode. After 1 hour, the patient reported that she could climb stairs without any other breathing problems and without needing to stop. Overall, she felt almost symptom-free and more energetic.

[0060] The patient has been symptom-free for the last 14 days; according to her assessment, the improvement in breathing and performance is approximately 80% compared to her previous condition.

[0061] The patient is currently undergoing follow-up therapy (biological regenerative medicine according to C. Klein) with the administration of a second nosode. Example 3: Patient Mr. F. from Berlin, born in 1997 A) Clinical picture

[0062] The patient had been suffering from ear pain with a feeling of pressure for three months, as well as right-sided difficulty swallowing. Serological tests were positive. The antibiotic prescribed by the general practitioner did not lead to any improvement. Subsequent, appropriate dysbiosis management was initiated and carried out. B) Nosode production on May 21, 2014

[0063] 0.5 ml of the patient's blood was dissolved in 5 ml of 70% ethanolic solution in a preparation vial and magnetically activated for 5 minutes using a vita-life® magnetic wand (available from VITA LIFE HandelsgmbH, Gewerbepark 1, 9220 Velden-Lind, Austria). The agents described below were then added while the magnetic wand was used for further activation. 10 drops of EBV nosode C30 0,5ml 10 drops of Sanukehl Staphylococcus D6 0,5ml 10 drops of ionic fluoride D6 0,5ml

[0064] The mixture was then shaken under continuous magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0065] A second addition of medication occurred as follows: 1 ampoule of folic acid forte Hevert 2,0ml 1 ampoule of Hypophysis / Stannum 1,0ml 20 drops of Q80 from Calendula 0,5ml

[0066] Then, this mixture was shaken under continued magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0067] A third addition of medication occurred as follows: 2 ampoules of para-benzoquinone from Heel 4,0ml 1 ampoule N. Vagus GI D6 Wala 2,0ml

[0068] Then, this mixture was shaken under continued magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0069] A fourth and final addition of medicines occurred as follows: 10 drops of Regenaplex 102 0,5ml 10 Arnica C30 globules 0,0 ml Total volume of added drugs 11,5ml

[0070] The modified autologous blood nosode thus obtained was then shaken under further continuous magnetic field activation by repeatedly striking the preparation glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen) and finally made up to 25 ml with 705 ethanol to obtain the modified final autologous blood nosode. C) Intake of the modified autologous blood nosode

[0071] The modified autologous blood nosode, prepared as described above, was administered orally to the patient, 15 drops three times daily, for a period of three days. The nosode must remain in the mouth for two minutes (to allow for salivation) without being swallowed. D) Treatment outcome according to the patient's statements

[0072] Just five minutes after taking the nosode, he observed a very clear to complete reduction in the pressure sensation in his ears, as well as a reduction in his difficulty swallowing. According to the patient, no further symptoms were present from that point on.

[0073] After a few days, the patient developed tinnitus, presumably caused by the cervical spine. An examination by an ENT specialist revealed no hearing problems or inflammation. The patient was given a corresponding recommendation for continued supportive therapy. No further information is available at this time. Example 4: Toddler, 2 1 / 2 years old A) Clinical picture

[0074] For two years, the child had been experiencing persistent paralysis, initially accompanied by extreme drowsiness. This began one day after a six-in-one vaccination administered by the pediatrician. Prior to this, the child had developed normally, sleeping and eating normally. Since the vaccination, the child had to be woken up to eat. Overall, the child's development was delayed, particularly in the feet. The child exhibited a high level of general aggression (hitting and screaming) and significant muscle tension.

[0075] Later, another pediatrician prescribed Hypophysis / Stannum globules, whereupon the toddler awoke from drowsiness and found a normal sleep rhythm. B) Nosode production on May 2, 2014

[0076] One drop of the child's blood was dissolved in 1 ml of physiological saline solution (0.9% NaCl solution) and magnetically activated for 5 minutes using a vita-life® magnetic wand (available from VITA LIFE HandelsgmbH, Gewerbepark 1, 9220 Velden-Lind, Austria). The agents described below were then added while the magnetic wand was used for further activation. 5 drops of ionized fluorine D6 0,5ml 1 ampoule of Hypophysis / Stannum from Wala 1,0ml

[0077] The mixture was then shaken under continuous magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0078] A second addition of medication occurred as follows: 1 drop of breath elixir, calendula herb garden 0,5ml 1 ampoule of folic acid forte from Hevert 2,0ml

[0079] Then, this mixture was shaken under continued magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0080] A third addition of medication occurred as follows: 3 tablets Mercurius solubilis C6 0,0ml 10 drops of ionized phosphorus D6 0,5ml 10 drops of ionized magnesium D6 0,5ml

[0081] Then, this mixture was shaken under continued magnetic field activation by repeatedly striking the sample glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, D-24568 Kaltenkirchen).

[0082] A fourth addition of medication occurred as follows: 1 ampoule of Cerebrum suis Injeel from Heel 2,0ml 10 drops of Regenaplex No. 109 0,5ml 10 drops of Regenaplex No. 112 0.5 mi Total volume of added drugs: 8 ml

[0083] The modified autologous blood nososde thus obtained was then shaken under further continuous magnetic field activation by repeatedly striking the preparation glass against a base 100 times and irradiated again for 1 minute with an FW-Pen according to Prof. Schaack, CE (Helzel Messtechnik GmbH, Carl-Benz-Straße 9, [ 24568 Kaltenkirchen).

[0084] Finally, two capsules containing 500 mg of L-ornithine each were added, thus producing the modified end autologous blood nosode. C) Intake of the modified autologous blood nosode

[0085] The modified autologous blood nosode, prepared as described above, was administered orally to the patient, 10 drops three times daily, for a period of 10 days. The nosode must remain in the mouth for 2 minutes (to mix with saliva) without being swallowed. D) Treatment outcome according to the statement of the patient's mother

[0086] After administration of the nosode, an immediate improvement in the child's emotional state occurred. The child no longer exhibited aggression, and a reduction in tension, further improvement in sleep, and a decrease in foot paralysis leading to normal development of the musculoskeletal system were observed. The child can now climb stairs and dress independently. Furthermore, the child has since begun playing with other children at kindergarten, which was not previously the case. Overall, normal development and an improvement in speech were observed.

[0087] For nosode therapy, a treatment recommendation of biological regeneration therapy was prescribed. This included mineral therapy as well as dysbiosis management.

[0088] The mother writes in a letter: "...From the day he first took the medication, we noticed a clear difference. He no longer has uncontrolled tantrums!! He is much more active, and he is also making significant progress in his development..... his kindergarten teachers confirm the progress. They say it's unbelievable, he's like a different child!!! ....He talks much more and, above all, better. He plays with other children!! He is no longer so withdrawn......he is making tremendous progress in his development."

Claims

1. Method for binding an active substance or an active agent to an activated autologous blood nosode, comprising: a) dissolving blood of a patient in an aqueous or aqueous / ethanolic medium or triturating blood of a patient with a carrier approved for globules according to the Homeopathic Pharmacopoeia (HAB) to obtain a first mixture; b) activating the first mixture by applying magnetic pulses with magnetic field period frequencies within a range of about 0.01 to about 20,000 Hz and field strengths of up to 50 µT to the first mixture to obtain an activated first mixture; c) adding one or more active substances and / or active agents to the activated first mixture to obtain a second mixture; d) succussing the second mixture by mechanical action, wherein steps c) and d) are performed under continuous application of the magnetic pulses and wherein steps c) and d) can be repeated once or multiple times, thereby obtaining a succussed second mixture; and e) activating the succussed second mixture by further continuously applying the magnetic pulses and irradiating the succussed second mixture with visible light of changing color generated by LEDs, thereby increasing the binding capacity of human serum albumin (HSA) in the blood to the active substance(s) and / or to at least parts of the active agent or active agents and obtaining a modified autologous blood nosode.

2. The method of claim 1, characterized in that the steps of adding one or more active agents / active substances to the initially prepared autologous blood nosode are repeated up to six or seven times.

3. The method of claim 1 or 2, characterized in that the active substance(s) or the active agent or active agents are selected from one or more members of the group of medicinal products consisting of nosodes, homeopathic medicinal products, and allopathic medicinal products.

4. The method of any one of claims 1 to 3, characterized in that the mechanical action in step e) is carried out in succession about 20 to about 200 times, preferably about 50 to about 150 times.

5. The method of any one of claims 1 to 4, characterized in that the activation by applying magnetic pulses comprises applying needle pulse packages with pauses in between.

6. The method of any one of claims 1 to 5, characterized in that the visible light of changing color generated by LEDs has a luminous intensity of about 4000 mcd and is irradiated for about 1 to about 5 minutes.

7. The method of any one of claims 1 to 6, characterized in that the visible light of changing color generated by LEDs further passes through a magnetic field downstream of the LEDs having a magnetic field strength of about 50 µT, which is additionally modulated by magnetic pulses with a field strength of 20 µT at frequencies in the range of 120-140 Hz and about 90 kHz.

8. Apparatus for carrying out the method of any one of claims 1 to 7, comprising: 1) a closable housing (2), 2) a sample holder (18) arranged in the housing, which can hold a transparent vessel (5) in which the first mixture (7) of step a) or b) is prepared or contained, 3) a device (15, 16) capable of repeatedly imparting a mechanical jolt and / or translational movement to the vessel, 4) a magnetic coil (10) capable of generating magnetic pulses directed at the vessel with magnetic field period frequencies in the range of about 0.01 to about 20,000 Hz and field strengths of up to 50 µT; and 5) a device (11) comprising LEDs (12) which can generate visible light with at least two colors and irradiate the generated light into the vessel (6).

9. The apparatus of claim 8, characterized in that the holder (18) and the device (15, 16) capable of repeatedly imparting a mechanical jolt and / or translational movement to the vessel are connected via an arm (17).

10. The apparatus of claim 8 or 9, characterized in that the magnetic coil (10) is arranged cylindrically around the vessel (5).

11. The apparatus of any one of claims 8 to 10, characterized in that the LEDs (12) are located in or on an LED strip (11) which is arranged helically on the side of the coil (10) facing the vessel.

12. Modified autologous blood nosode obtainable according to the method of any one of claims 1 to 7.